Flu Vaccination Advice Issued Amid ACIP Impasse
Medical groups have released seasonal guidance for older adults as federal vaccine policy remains in limbo.
Updated on Sept. 18, 2026 in COVID-19
Live Poll
Is October the best time for you to receive an annual flu vaccine?
Following a federal judge's March ruling that blocked new Advisory Committee on Immunization Practices (ACIP) selections, medical experts have issued independent guidance for the upcoming respiratory season. These recommendations provide clarity for older adults navigating flu shot options while federal oversight remains stalled.
Why it matters
The absence of formal federal panel guidance creates uncertainty for clinicians and patients, making professional consensus essential for navigating this year's immunization choices. Experts aim to ensure that vulnerable groups receive science-based recommendations ahead of the peak influenza months.
The FDA's accelerated approval of the mRNA influenza vaccine for those aged 65 and older was based on a smaller study evaluating immunogenicity relative to existing high-dose vaccines. This finding is preliminary, with further confirmatory trial data required to establish long-term clinical efficacy.
The players
William Schaffner
An infectious disease expert at Vanderbilt University Medical Center specializing in vaccine policy.
Paul A. Offit
A pediatrician and vaccine expert at Children's Hospital of Philadelphia who serves on national advisory boards.
Aaron E. Glatt
A physician at Mount Sinai South Nassau focused on infectious diseases and hospital epidemiology.
Moderna
A biotechnology company that develops mRNA-based therapeutics and newly approved influenza vaccines.
Advisory Committee on Immunization Practices (ACIP)
A federal panel that provides vaccine recommendations for the United States population.
The details
The new mRNA influenza vaccine works by using messenger RNA to instruct cells to produce influenza proteins, stimulating a targeted immune response. It joins a suite of options for adults 65 and older, including recombinant and adjuvanted formulations, which generally offer stronger protection than standard-dose vaccines. The vaccine is also approved for adults aged 50 to 64, though patients should allow two weeks for immunity to develop before potential exposure.
Timeline
March 2026: Federal judge blocked ACIP selections.
August 2026: FDA approved mRNA influenza vaccine.
September 2026: Article published regarding fall vaccination advice.
October 2026: Expert recommended window for flu vaccination.
February/March 2027: Period when flu is often most common.
Health Landscape
This development follows the March 2026 federal court ruling that disrupted the established process for setting national vaccine policy. It highlights the shift toward interim, expert-led guidance in the face of institutional regulatory stalls.
Older adults and those aged 50 to 64 should speak with their doctor about which influenza vaccine formulation is most appropriate for their health history. Because full protection requires two weeks to develop, aiming for vaccination by the October window remains a priority for personal prevention.
The takeaway
While federal panel guidance is currently delayed, professional medical consensus remains an essential resource for selecting this year's flu shot. Patients should consult their primary care physician to discuss their personal risk factors and the timing of their vaccination for maximum protection.
Further reading
Learn more about seasonal immunization strategies in the COVID-19 section.
Live Poll
Is October the best time for you to receive an annual flu vaccine?
